Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
Date:2/26/2013

ont and milestone payments previously received from Pfizer.  These deferred revenues were recognized in the fourth quarter as a result of the previously announced agreement to mutually terminate the collaboration agreement.  Testim U.S. revenue increased by 3% in the quarter to $58.4 million while XIAFLEX U.S. revenue increased 30% over the fourth quarter of 2011 to $17.5 million.  See Table 3 attached for further details on revenues.

Gross margin on net revenues was 84% for the quarter ended December 31, 2012 compared to 77% for the comparable period in 2011.  This increase in the gross margin rate is due to the impact of the $93.6 million in deferred revenues, offset by $8.4 million of related deferred costs, recognized as a result of the agreement to mutually terminate the Company's agreement with Pfizer. Excluding this impact, the gross margin rate declined primarily due to costs incurred in 2012 for XIAFLEX manufacturing initiatives partially offset by the impact of year-over-year net price increases on Testim U.S. product sales.

Research and development spending for the quarter ended December 31, 2012 was $13.2 million, compared to $18.7 million for 2011.  This decrease in expense results principally from a reduction in 2012 of activities related to development of a larger scale XIAFLEX production process.

Selling, general and administrative costs for the quarter ended December 31, 2012 were $40.7  million, compared to $50.1 million in the comparable 2011 period.  This decrease was primarily due to a lower level of spending in 2012 on XIAFLEX marketing and costs incurred in 2011 related to management changes, offset in part by costs incurred in 2012 related to the relocation of the company's headquarters.

Net income for the fourth quarter of 2012 was $90.5 million, or $1.83 per share, fully diluted, compared to a net loss of $(11.9) million, or $(0.25) per share, fully diluted, reported for the f
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Auxilium Announces Appointments to Enhance Leadership Team
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
7. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Pittcon is ... MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have organized ... September 5, 2014. JASIS , Asia’s largest analytical ... 2014, in Makuhari Messe, Japan. , The four ... for Bioanalysis from Single Molecules to Single Cells” will ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Due to a ... last week, the Adult Stem Cell Technology Center, LLC ( ... support stem cell therapy research that might benefit ALS patients. ... cells for new stem cell technologies and therapeutic applications, FRC ... Ice Bucket Challenge donors who wish not to support ...
(Date:8/28/2014)... Best Sanitizers, Inc., a leader in hand ... is asking industry professionals to prepare for fall harvest ... soap they’re currently using to the Best Sanitizers’ ... hygiene is critical to fighting cross-contamination and the spread ... criteria are identified to evaluate the effectiveness of an ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... paper,published today, scientists at deCODE genetics (Nasdaq: ... a novel insight into the connection,between inflammation and ... Icelanders, the deCODE team discovered several common single-letter,variations ... that increase levels of,eosinophils in the bloodstream. These ...
... Feb. 9 Aerovance Inc. today announced the appointment ... senior vice president and chief medical officer.Dr. Otulana, 52, ... leadership to the company as it moves forward with ... for severe atopic eczema. He has more than 20 ...
... plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty ... 2009. , , Results press release will be ... Investor meeting and conference call time: 14:00 GMT ... meeting and conference call: , Angus Russell, ...
Cached Biology Technology:Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack 2Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack 3Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack 4Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer 2Full Year 2008 Results Date Notification - 19 February 2008 2
(Date:9/1/2014)... Mass-- Conventional wisdom has long held that corals ... coral reefs are passive organisms that rely ... such as nutrients and oxygen. But now scientists ... (WIS) in Israel have found that they are ... water into turbulent patterns that greatly enhance their ...
(Date:9/1/2014)... As nocturnal animals, bats are perfectly adapted to a life ... between the reflected echoes to measure distance to obstacles or ... different echo delays. A study carried out by researchers at ... that this map dynamically adapts to external factors. , ... bat flies in too close to an object, the number ...
(Date:8/31/2014)... of the greatest challenges in modern medicine is developing ... with minimal toxicity and side-effects to the patient. Such ... the drug molecule. Ideally, the drug should have a ... so that it binds it with high specificity. Publishing ... a synthetic amino acid that can impact the 3D ...
Breaking Biology News(10 mins):Nature's tiny engineers 2Nature's tiny engineers 3Zooming in for a safe flight 2A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3
... A man,s height is a modest marker for ... linked to progression of the cancer, say British researchers ... also reviewed 58 published studies. In the September ... a journal of the American Association for Cancer Research, ...
... widely cultivated crop that has been subjected to intensive ... years ago). The domestication of grapevine has undergone a ... The recent publication of the complete grapevine genome ... its content. This sequencing has shown that genes constitute ...
... discovered that a gene controlling whether blood vessels differentiate ... to a vascular disorder in the brain that causes ... and the new findings are the first to provide ... particular brain disorder, known as BAVM, and to provide ...
Cached Biology News:Height linked to risk of prostate cancer development and progression 2Gene is likely cause of stroke-inducing vascular malformations 2Gene is likely cause of stroke-inducing vascular malformations 3
Blimp-1 (H-150)...
... /K + ATPase α-1, clone C464.6 ... Immunogen : Purified Na + /K + ... rabbit kidney outer medulla Formulation: 0.1M Tris-glycine, ... azide Quality Assurance: routinely evaluated in immunoblot ...
Immunogen: Purified native p24 from strain IIIB. Storage: -20 C, Avoid Freeze/Thaw Cycles...
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Biology Products: